Key Abstracts in GU Cancers at ASCO24

Key Abstracts in GU Cancers at ASCO24

Up next

Personalizing Treatment in Head and Neck Cancers

Dr. Monty Pal and Dr. Ari Rosenberg discuss the evolution of treatment strategies in head and neck cancers, including the challenges of treating both HPV-positive and HPV-negative disease and the emergence of blood-based biomarkers to advance personalized therapy across different ...  Show more

Can Low-Dose Immunotherapy Expand Global Access to Cancer Care?

Dr. Monty Pal and Dr. Atul Batra discuss the PLANeT study from India, which evaluated low-dose pembrolizumab in addition to neoadjuvant chemotherapy for triple-negative breast cancer, and its place among a growing body of international research on improving efficacy while reducin ...  Show more

Recommended Episodes

Podcast 300: NADIM II trial offers “quite exciting” results in lung cancer
Clinical Conversations

A VIDEO RECORDING OF THIS INTERVIEW IS AVAILABLE HERE.

We’re back with another interview from this year’s IASLC conference.

This time, Christine Sadlowski and Dr. Julia Rotow interview Dr. Mar ...

  Show more

Treatment of Metastatic Colorectal Cancer Guideline
ASCO Guidelines

An interview with Dr. Van Morris from The University of Texas MD Anderson Cancer Center in Houston, TX and Dr. Cathy Eng from Vanderbilt-Ingram Cancer Center in Nashville, TN, co-chairs on "Treatment of Metastatic Colorectal Cancer: ASCO Guideline." Dr. Morris and Dr. Eng review ...  Show more

Immunotherapy and Biomarker Testing in Recurrent and Metastatic Head and Neck Cancers Guideline
ASCO Guidelines

Dr. Emrullah Yilmaz reviews the latest evidence and recommendations for health care providers on biomarker testing and immunotherapy for head and neck cancers. He discusses the ASCO Expert Panel's recommendations for biomarkers for the selection of patients with head and neck squ ...  Show more

Management of Stage III NSCLC Rapid Recommendation Update
ASCO Guidelines

Dr. Navneet Singh joins us again, this time to discuss the rapid recommendation update for stage III non-small cell lung cancer, incorporating updated data presented at the 2023 ASCO Annual Meeting. He discusses the new trials that prompted the guideline update and updated recomm ...  Show more